Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody JS016 in Hospitalized Chinese Patients with COVID-19: a Phase 2/3, Multicenter, Randomized, Open-Label, Controlled Trial
Run Dong, Li Jiang, Ting Yang, Changsong Wang, Yi Zhang, Xu Chen, Jianfeng Xie, Yuanbin Guo, Li Weng, Yan Kang, Kaijiang Yu, Haibo Qiu, Bin Du
Recombinant human severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibody JS016 showed neutralizing and therapeutic effects in preclinical studies. The clinical efficacy and safety of the therapy needed to be evaluated. In this phase 2/3, multicenter, randomized, open-label, controlled trial, hospitalized patients with moderate or severe coronavirus disease 2019 (COVID-19) were randomly assigned in a 1:1 ratio to receive standard care or standard care plus a single intravenous infusion of JS016. The primary outcome was a six-level ordinal scale of clinical status on day 28 since randomization. Secondary outcomes include adverse events, 28-day mortality, ventilator-free days within 28 days, length of hospital stay, and negative conversion rate of SARS-CoV-2 nucleic acid on day 14. A total of 199 patients were randomized, and 197 (99 in the JS016 group and 98 in the control group) were analyzed. Most patients, 95 (96%) in the JS016 group and 97 (99%) in the control group were in the best category on day 28 since randomization. The odds ratio of being in a better clinical status was 0.31 (95% confidence interval [CI], 0.03 to 3.19; P = 0.33). Few adverse events occurred in both groups (3% in the JS016 group and 1% in the control group, respectively; P = 0.34). SARS-CoV-2 neutralizing antibody JS016 did not show clinical efficacy among hospitalized Chinese patients with moderate to severe COVID-19 disease. Further studies are needed to assess the efficacy of the neutralizing antibody to prevent disease deterioration and its benefits among groups of patients specified by disease course and severity. (This study has been registered at ClinicalTrials.gov under identifier NCT04931238.)
References
Baral, Yin, James, Treatment and prevention strategies for the COVID 19 pandemic: a review of immunotherapeutic approaches for neutralizing SARS-CoV-2, Int J Biol Macromol,
doi:10.1016/j.ijbiomac.2021.07.013Baum, Fulton, Wloga, Copin, Pascal et al., Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies, Science,
doi:10.1126/science.abd0831Beigel, Tebas, Elie-Turenne, Bajwa, Bell et al., Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study, Lancet Respir Med,
doi:10.1016/S2213-2600(17)30174-1Bian, Zheng, Wei, Wen, Zhang et al., Safety and efficacy of meplazumab in healthy volunteers and COVID-19 patients: a randomized phase 1 and an exploratory phase, Signal Transduct Target Ther,
doi:10.1038/s41392-021-00603-6Cao, Wang, Wen, Liu, Wang et al., A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2001282Cavalcanti, Zampieri, Rosa, Azevedo, Veiga et al., Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2019014Chen, Nirula, Heller, Gottlieb, Boscia et al., Investigators B-1. 2020. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2029849Chen, Winkler, Case, Aziati, Bricker et al., In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains, Nature,
doi:10.1038/s41586-021-03720-yChen, Zhou, Dong, Qu, Gong et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, Lancet,
doi:10.1016/S0140-6736(20)30211-7Copin, Baum, Wloga, Pascal, Giordano et al., The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies, Cell,
doi:10.1016/j.cell.2021.06.002Dall'acqua, Kiener, Wu, Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn)*, J Biol Chem,
doi:10.1074/jbc.M604292200Docherty, Harrison, Green, Hardwick, Pius et al., Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study, BMJ,
doi:10.1136/bmj.m1985Dougan, Nirula, Azizad, Mocherla, Gottlieb et al., Blaze-1 Investigators. 2021. Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2102685Feng, Ling, Bai, Xie, Huang et al., COVID-19 with Different Severity: a Multi-center Study of Clinical Features, Am J Respir Crit Care Med,
doi:10.1164/rccm.202002-0445OCGottlieb, Nirula, Chen, Boscia, Heller et al., Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19, JAMA,
doi:10.1001/jama.2021.0202Group, Horby, Mafham, Peto, Campbell et al., Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, Medrxiv,
doi:10.1101/2021.06.15.21258542Guan, Ni, Hu, Liang, Ou et al., Clinical Characteristics of Coronavirus Disease 2019 in China, N Engl J Med,
doi:10.1056/NEJMoa2002032Holmes, Hurt, Dobbie, Clinch, Oxford et al., Understanding the Impact of Resistance to Influenza Antivirals, Clin Microbiol Rev,
doi:10.1128/CMR.00224-20Lundgren, Grund, Barkauskas, Holland, Gottlieb et al., A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19, N Engl J Med
Lundgren, Grund, Barkauskas, Holland, Gottlieb et al., Clinical and Virological Response to a Neutralizing Monoclonal Antibody for Hospitalized Patients with COVID-19, Medrxiv,
doi:10.1101/2021.07.19.21260559Planas, Veyer, Baidaliuk, Staropoli, Guivel-Benhassine et al., Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization, Nature,
doi:10.1038/s41586-021-03777-9Richardson, Hirsch, Narasimhan, Crawford, Mcginn et al., Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area, JAMA,
doi:10.1001/jama.2020.6775Ruan, Yang, Wang, Jiang, Song, Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China Intensive Care Medicine
Shi, Shan, Duan, Chen, Liu et al., A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2, Nature,
doi:10.1038/s41586-020-2381-ySiemieniuk, Bartoszko, Martinez, Kum, Qasim et al., Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis, BMJ,
doi:10.1136/bmj.n2231Starr, Greaney, Addetia, Hannon, Choudhary et al., Prospective mapping of viral mutations that escape antibodies used to treat COVID-19, Science,
doi:10.1126/science.abf9302Wang, Casner, Nair, Wang, Yu et al., Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization, Cell Host Microbe,
doi:10.1016/j.chom.2021.04.007Wang, Fan, Salam, Horby, Hayden et al., Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically ill patients with influenza virus infection, J Infect Dis,
doi:10.1093/infdis/jiz656Wang, Hu, Hu, Zhu, Liu et al., Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China, JAMA,
doi:10.1001/jama.2020.1585Wang, Zhang, Ge, Ren, Zhang et al., SARS-CoV-2 variants resist antibody neutralization and broaden host ACE2 usage, BioRxiv,
doi:10.1101/2021.03.09.434497Weinreich, Sivapalasingam, Norton, Ali, Gao et al., REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2035002Wu, Li, Wang, Liu, Yu et al., Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab, in. Chinese Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study, Antimicrob Agents Ch
Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet,
doi:10.1016/S0140-6736(20)30566-3DOI record:
{
"DOI": "10.1128/aac.02045-21",
"ISSN": [
"0066-4804",
"1098-6596"
],
"URL": "http://dx.doi.org/10.1128/aac.02045-21",
"abstract": "<jats:p>Recombinant human severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibody JS016 showed neutralizing and therapeutic effects in preclinical studies. The clinical efficacy and safety of the therapy needed to be evaluated.</jats:p>",
"alternative-id": [
"10.1128/aac.02045-21"
],
"article-number": "e02045-21",
"assertion": [
{
"group": {
"label": "Publication History",
"name": "publication_history"
},
"label": "Received",
"name": "received",
"order": 0,
"value": "2021-10-19"
},
{
"group": {
"label": "Publication History",
"name": "publication_history"
},
"label": "Accepted",
"name": "accepted",
"order": 1,
"value": "2022-01-24"
},
{
"group": {
"label": "Publication History",
"name": "publication_history"
},
"label": "Published",
"name": "published",
"order": 2,
"value": "2022-03-15"
}
],
"author": [
{
"affiliation": [
{
"name": "Medical Intensive Care Unit, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, People’s Republic of China"
}
],
"family": "Dong",
"given": "Run",
"sequence": "first"
},
{
"affiliation": [
{
"name": "Department of Critical Care Medicine, Xuanwu Hospital, Capital Medical University, Beijing, People’s Republic of China"
}
],
"family": "Jiang",
"given": "Li",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Medical Intensive Care Unit, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, People’s Republic of China"
}
],
"family": "Yang",
"given": "Ting",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Intensive Care Unit, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, People’s Republic of China"
}
],
"family": "Wang",
"given": "Changsong",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Department of Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China"
}
],
"family": "Zhang",
"given": "Yi",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Intensive Care Unit, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, People’s Republic of China"
}
],
"family": "Chen",
"given": "Xu",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Department of Critical Care Medicine, Zhongda Hospital, Southeast University, Nanjing, Jiangsu, People’s Republic of China"
}
],
"family": "Xie",
"given": "Jianfeng",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Intensive Care Unit, Shijiazhuang People’s Hospital, Shijiangzhuang, Hebei, People’s Republic of China"
}
],
"family": "Guo",
"given": "Yuanbin",
"sequence": "additional"
},
{
"ORCID": "https://orcid.org/0000-0003-0403-0752",
"affiliation": [
{
"name": "Medical Intensive Care Unit, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, People’s Republic of China"
}
],
"authenticated-orcid": true,
"family": "Weng",
"given": "Li",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Department of Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China"
}
],
"family": "Kang",
"given": "Yan",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Intensive Care Unit, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, People’s Republic of China"
}
],
"family": "Yu",
"given": "Kaijiang",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Department of Critical Care Medicine, Zhongda Hospital, Southeast University, Nanjing, Jiangsu, People’s Republic of China"
}
],
"family": "Qiu",
"given": "Haibo",
"sequence": "additional"
},
{
"ORCID": "https://orcid.org/0000-0001-6237-2895",
"affiliation": [
{
"name": "Medical Intensive Care Unit, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, People’s Republic of China"
}
],
"authenticated-orcid": true,
"family": "Du",
"given": "Bin",
"sequence": "additional"
},
{
"affiliation": [],
"name": "for the China Critical Care Clinical Trials Group (CCCCTG)",
"sequence": "additional"
}
],
"container-title": "Antimicrobial Agents and Chemotherapy",
"container-title-short": "Antimicrob Agents Chemother",
"content-domain": {
"crossmark-restriction": true,
"domain": [
"journals.asm.org"
]
},
"created": {
"date-parts": [
[
2022,
2,
22
]
],
"date-time": "2022-02-22T16:29:06Z",
"timestamp": 1645547346000
},
"deposited": {
"date-parts": [
[
2022,
3,
15
]
],
"date-time": "2022-03-15T15:03:49Z",
"timestamp": 1647356629000
},
"funder": [
{
"DOI": "10.13039/501100011930",
"award": [
"B17245-043"
],
"doi-asserted-by": "publisher",
"id": [
{
"asserted-by": "publisher",
"id": "10.13039/501100011930",
"id-type": "DOI"
}
],
"name": "Beijing Medical and Health Foundation"
},
{
"DOI": "10.13039/501100002855",
"award": [
"2021YFC0863100"
],
"doi-asserted-by": "publisher",
"id": [
{
"asserted-by": "publisher",
"id": "10.13039/501100002855",
"id-type": "DOI"
}
],
"name": "Ministry of Science and Technology of the People's Republic of China"
}
],
"indexed": {
"date-parts": [
[
2025,
10,
28
]
],
"date-time": "2025-10-28T15:12:59Z",
"timestamp": 1761664379153,
"version": "3.41.2"
},
"is-referenced-by-count": 7,
"issue": "3",
"issued": {
"date-parts": [
[
2022,
3,
15
]
]
},
"journal-issue": {
"issue": "3",
"published-print": {
"date-parts": [
[
2022,
3,
15
]
]
}
},
"language": "en",
"license": [
{
"URL": "https://creativecommons.org/licenses/by/4.0/",
"content-version": "vor",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2022,
3,
15
]
],
"date-time": "2022-03-15T00:00:00Z",
"timestamp": 1647302400000
}
},
{
"URL": "https://journals.asm.org/non-commercial-tdm-license",
"content-version": "tdm",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2022,
3,
15
]
],
"date-time": "2022-03-15T00:00:00Z",
"timestamp": 1647302400000
}
}
],
"link": [
{
"URL": "https://journals.asm.org/doi/pdf/10.1128/aac.02045-21",
"content-type": "application/pdf",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "https://journals.asm.org/doi/pdf/10.1128/aac.02045-21",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "235",
"original-title": [],
"prefix": "10.1128",
"published": {
"date-parts": [
[
2022,
3,
15
]
]
},
"published-print": {
"date-parts": [
[
2022,
3,
15
]
]
},
"publisher": "American Society for Microbiology",
"reference": [
{
"DOI": "10.1056/NEJMoa2002032",
"doi-asserted-by": "publisher",
"key": "e_1_3_3_2_2"
},
{
"DOI": "10.1001/jama.2020.1585",
"doi-asserted-by": "publisher",
"key": "e_1_3_3_3_2"
},
{
"DOI": "10.1016/S0140-6736(20)30566-3",
"doi-asserted-by": "publisher",
"key": "e_1_3_3_4_2"
},
{
"DOI": "10.1016/S0140-6736(20)30183-5",
"doi-asserted-by": "publisher",
"key": "e_1_3_3_5_2"
},
{
"article-title": "Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan",
"author": "Ruan Q",
"first-page": "1",
"journal-title": "China Intensive Care Medicine",
"key": "e_1_3_3_6_2",
"unstructured": "Ruan Q, Yang K, Wang W, Jiang L, Song J. 2020. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan. China Intensive Care Medicine 368:1–3.",
"volume": "368",
"year": "2020"
},
{
"DOI": "10.1164/rccm.202002-0445OC",
"doi-asserted-by": "publisher",
"key": "e_1_3_3_7_2"
},
{
"DOI": "10.1016/S0140-6736(20)30211-7",
"doi-asserted-by": "publisher",
"key": "e_1_3_3_8_2"
},
{
"DOI": "10.1136/bmj.m1985",
"doi-asserted-by": "publisher",
"key": "e_1_3_3_9_2"
},
{
"DOI": "10.1001/jama.2020.6775",
"doi-asserted-by": "publisher",
"key": "e_1_3_3_10_2"
},
{
"DOI": "10.1056/NEJMoa2021436",
"doi-asserted-by": "publisher",
"key": "e_1_3_3_11_2"
},
{
"DOI": "10.1038/s41586-020-2381-y",
"doi-asserted-by": "publisher",
"key": "e_1_3_3_12_2"
},
{
"article-title": "Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab, in",
"author": "Wu X",
"journal-title": "Chinese Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study Antimicrob Agents Ch",
"key": "e_1_3_3_13_2",
"unstructured": "Wu X, Li N, Wang G, Liu W, Yu J, Cao G, Wang J, Chen Y, Ma J, Wu J, Yang H, Mao X, He J, Yu Y, Qiu C, Li N, Yao S, Feng H, Yan J, Zhang W, Zhang J. 2021. Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab, in. Chinese Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study Antimicrob Agents Ch 65:e00350-21.",
"volume": "65",
"year": "2021"
},
{
"DOI": "10.1016/j.ijbiomac.2021.07.013",
"doi-asserted-by": "publisher",
"key": "e_1_3_3_14_2"
},
{
"DOI": "10.3390/v13040628",
"doi-asserted-by": "publisher",
"key": "e_1_3_3_15_2"
},
{
"DOI": "10.1136/bmj.n2231",
"doi-asserted-by": "publisher",
"key": "e_1_3_3_16_2"
},
{
"DOI": "10.1056/NEJMoa2029849",
"doi-asserted-by": "publisher",
"key": "e_1_3_3_17_2"
},
{
"DOI": "10.1056/NEJMoa2033130",
"doi-asserted-by": "publisher",
"key": "e_1_3_3_18_2"
},
{
"DOI": "10.1001/jama.2021.0202",
"doi-asserted-by": "publisher",
"key": "e_1_3_3_19_2"
},
{
"DOI": "10.1056/NEJMoa2102685",
"doi-asserted-by": "publisher",
"key": "e_1_3_3_20_2"
},
{
"DOI": "10.1101/2021.07.19.21260559",
"doi-asserted-by": "publisher",
"key": "e_1_3_3_21_2"
},
{
"DOI": "10.1056/NEJMoa2035002",
"doi-asserted-by": "publisher",
"key": "e_1_3_3_22_2"
},
{
"DOI": "10.1101/2021.06.15.21258542",
"doi-asserted-by": "publisher",
"key": "e_1_3_3_23_2"
},
{
"DOI": "10.1128/CMR.00224-20",
"doi-asserted-by": "publisher",
"key": "e_1_3_3_24_2"
},
{
"DOI": "10.1126/science.abd0831",
"doi-asserted-by": "publisher",
"key": "e_1_3_3_25_2"
},
{
"DOI": "10.1126/science.abf9302",
"doi-asserted-by": "publisher",
"key": "e_1_3_3_26_2"
},
{
"DOI": "10.1016/j.cell.2021.06.002",
"doi-asserted-by": "publisher",
"key": "e_1_3_3_27_2"
},
{
"DOI": "10.1074/jbc.M604292200",
"doi-asserted-by": "publisher",
"key": "e_1_3_3_28_2"
},
{
"DOI": "10.1038/s41392-021-00603-6",
"doi-asserted-by": "publisher",
"key": "e_1_3_3_29_2"
},
{
"DOI": "10.1038/s41586-021-03777-9",
"doi-asserted-by": "publisher",
"key": "e_1_3_3_30_2"
},
{
"DOI": "10.1038/s41586-021-03398-2",
"doi-asserted-by": "publisher",
"key": "e_1_3_3_31_2"
},
{
"DOI": "10.1101/2021.03.09.434497",
"doi-asserted-by": "crossref",
"key": "e_1_3_3_32_2",
"unstructured": "Wang R Zhang Q Ge J Ren W Zhang R Lan J Ju B Su B Yu F Chen P Liao H Feng Y Li X Shi X Zhang Z Zhang F Ding Q Zhang T Wang X Zhang L. 2021. SARS-CoV-2 variants resist antibody neutralization and broaden host ACE2 usage. BioRxiv. 10.1101/2021.03.09.434497."
},
{
"DOI": "10.1038/s41586-021-03720-y",
"doi-asserted-by": "publisher",
"key": "e_1_3_3_33_2"
},
{
"DOI": "10.1016/j.chom.2021.04.007",
"doi-asserted-by": "publisher",
"key": "e_1_3_3_34_2"
},
{
"DOI": "10.1016/S2213-2600(17)30174-1",
"doi-asserted-by": "publisher",
"key": "e_1_3_3_35_2"
},
{
"DOI": "10.1093/infdis/jiz656",
"doi-asserted-by": "publisher",
"key": "e_1_3_3_36_2"
},
{
"DOI": "10.1056/NEJMoa2001282",
"doi-asserted-by": "publisher",
"key": "e_1_3_3_37_2"
},
{
"DOI": "10.1056/NEJMoa2019014",
"doi-asserted-by": "publisher",
"key": "e_1_3_3_38_2"
}
],
"reference-count": 37,
"references-count": 37,
"relation": {},
"resource": {
"primary": {
"URL": "https://journals.asm.org/doi/10.1128/aac.02045-21"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [],
"subtitle": [],
"title": "Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody JS016 in Hospitalized Chinese Patients with COVID-19: a Phase 2/3, Multicenter, Randomized, Open-Label, Controlled Trial",
"type": "journal-article",
"update-policy": "https://doi.org/10.1128/asmj-crossmark-policy-page",
"volume": "66"
}
